Recent studies have pointed to a prognostic role of the astrocyte-specific biomarker chitinase 3-like 1 (CHI3L1) in patients with clinically isolated syndrome (CIS)1,2. This evidence concerns the gene CHI3L1 and in situ carcinoma.